01—Abstract
Summary
Summary of the 10-K filed February 21, 2012. Cited figures are marked; the original filing is the authoritative source.
Abbott Laboratories' 2011 10-K filing highlights a year of significant strategic moves and operational performance.
The company announced its intention to separate into two independent publicly traded companies: one focused on diversified medical products (retaining the Abbott name) and the other on research-based pharmaceuticals. This strategic maneuver is expected to unlock value and allow each entity to better focus on its respective growth opportunities. Financially, Abbott demonstrated robust sales growth, driven by its Proprietary Pharmaceutical Products segment, particularly the strong performance of Humira.
The company also benefited from strategic acquisitions, including Solvay Pharmaceuticals and Piramal Healthcare Limited's Healthcare Solutions business, which expanded its global reach and product portfolio, especially in emerging markets. Despite facing challenges such as patent expirations for certain products and increased generic competition, Abbott's diversified business model, strong product pipeline, and ongoing investment in research and development position it for continued growth.
02—Key points
Key Highlights
- Abbott announced plans to split into two publicly traded companies by the end of 2012: one for diversified medical products and one for research-based pharmaceuticals.
- Humira continued to be a significant revenue driver, with worldwide sales reaching $7.9 billion in 2011, representing a 19% increase from 2010.
- The company completed strategic acquisitions of Solvay Pharmaceuticals and Piramal Healthcare Limited's Healthcare Solutions business, bolstering its global presence and product offerings.
- Sales in the Proprietary Pharmaceutical Products segment increased by 11.0% in 2011, largely driven by Humira and growth in international markets.
- Research and development expenses increased by 10.9% to $4.1 billion in 2011, reflecting continued investment in new product development across key therapeutic areas.
- The company recorded a significant litigation charge of $1.5 billion related to ongoing settlement discussions in the U.S. government's investigation into Depakote sales and marketing activities.
- Abbott maintained strong financial health with net sales of $38.9 billion and net earnings of $4.7 billion in 2011.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in FY2011, Abbott Laboratories kept $0.22.
- Revenue$21.41B100.0%
- Cost of revenue−$10.02B46.8%
- Gross profit$11.39B53.2%
- Operating costs−$9.76B45.6%
- Operating income$1.63B7.6%
- Interest, other & tax$3.08B14.4%
- Net income$4.71B22.0%
Where FY2011 revenue went
$21.41B- Cost of revenue: $10.02B, 47% of revenue
- SG&A: $7.37B, 34% of revenue
- Operating income: $1.63B, 7.6% of revenue
- Other operating costs: $2.40B, 11% of revenue
Kept 7.6% as operating incomeOperating income $1.63B · 7.6%
Full revenue history →04—Financials
Financial Highlights
Figures from 10-KFY2011filed February 21, 2012Financial Statements
FY2011 against FY2010
| Line item | FY2011FY2010 | Change |
|---|---|---|
| Revenue | $21.41B$35.17B | −39.1% |
| Cost of Revenue | $10.02B$14.67B | −31.7% |
| Gross Profit | $11.39B$20.50B | −44.4% |
| SG&A Expenses | $7.37B$10.38B | −29.0% |
| Operating Expenses | $19.78B$29.08B | −32.0% |
| Operating Income | $1.63B$6.09B | −73.2% |
| Interest Expense | $359.00M$553.13M | −35.1% |
| Net Income | $4.71B$4.63B | +1.9% |
| EPS (Basic) | $3.03$2.98 | +1.7% |
| EPS (Diluted) | $3.01$2.96 | +1.7% |
| Shares Outstanding (Basic) | 1.56B1.55B | +0.7% |
| Shares Outstanding (Diluted) | 1.57B1.56B | +0.7% |
05—Questions
Frequently Asked Questions
What is the most significant strategic development for Abbott Laboratories as of this filing?
The most significant strategic development announced in 2011 was the plan to separate Abbott Laboratories into two independent, publicly traded companies. One company will focus on diversified medical products, including diagnostics, nutritionals, and medical devices, while the other will focus on research-based pharmaceuticals. This separation was expected to be completed by the end of 2012.
Which products were the primary growth drivers for Abbott in 2011?
Humira was the key growth driver within the Proprietary Pharmaceutical Products segment, showing strong performance across various indications. Additionally, acquisitions like Solvay Pharmaceuticals and Piramal Healthcare contributed significantly to overall sales growth, particularly in international markets.
What is the company's stance on the Depakote investigation and its associated financial impact?
Abbott recorded a $1.5 billion litigation charge in 2011 related to ongoing settlement discussions concerning the U.S. government's investigation into Depakote sales and marketing activities. While the resolution is expected to be material to cash flows in a given year, management believed its ultimate resolution would not have a material adverse effect on the company's overall financial position or results of operations, although specific impacts on cash flows are noted.
How did the company's R&D spending trend in 2011?
Research and development expenses increased by 10.9% to $4.1 billion in 2011, reflecting Abbott's commitment to advancing its pipeline across various segments, with a majority of the expenditures concentrated on proprietary pharmaceutical products.
06—Continue